Response to Comment on Beltrand et al. Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. Diabetes Care 2015;38:2033–2041
Authors:
Open Access
- 12 August 2016
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 39 (9) , e155
Abstract
We would like to respond to the comment made by Beltrand et al. (1). In our study (2), we hypothesized that a successful switch from insulin to sulfonylurea therapy in patients with neonatal diabetes owing to KATP channel mutations would improve neurodevelopmental parameters. It was a prospective single-center cohort study of patients switched from insulin to sulfonylurea therapy. The inclusion criterion was neonatal diabetes owing to a mutation in the KCNJ11 or ABCC8 gene. We did not anticipate the neuropsychological changes …Keywords
This publication has 4 references indexed in Scilit:
- Comment on Beltrand et al. Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations. Diabetes Care 2015;38:2033–2041Diabetes Care, 2016
- Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel MutationsDiabetes Care, 2015
- Visuomotor Performance in KCNJ11-Related Neonatal Diabetes Is Impaired in Children With DEND-Associated Mutations and May Be Improved by Early Treatment With SulfonylureasDiabetes Care, 2012
- Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutationDiabetic Medicine, 2008